|
Arthritis, lupus and asthma data a shot in arm for AstraZeneca
Reuters Benralizumab and tralokinumab both showed improvements in control of asthma in patients with specific, severe forms of the breathing disorder. All the drugs are being developed by MedImmune, the U.S.-based biotech company acquired by AstraZeneca in … |
View full post on asthma – Google News